Table 1.
Name | Manufacturer | MIGS Type | IOP reduction (%)* | Reduction in No. of Medications* | Study Data Available* | AAO Recommendation | Cochrane recommendation |
---|---|---|---|---|---|---|---|
iStent (1st generation)
|
Glaukos, Laguna Hills, CA | Non-Bleb Forming, Trabecular Meshwork Canal Implant | 8.2 – 27.3** | 0.35 – 2.2** | Prospective and Retrospective | No Recommendation | Very Low° |
iStent inject | Glaukos, Laguna Hills, CA | Non-Bleb Forming, Trabecular Meshwork Canal Implant | 15.8 – 48.4 | 1.2 – 2.4 | Prospective and Retrospective | I-, Insufficient Quality, Strong Recommendation | Very Low° |
iStent infinite † | Glaukos, Laguna Hills, CA | Non-Bleb Forming, Trabecular Meshwork Canal Implant | 20.5 – 30.3 | 2.21 – 3.99 | Prospective | Not Evaluated | Not Evaluated |
Hydrus | Alcon, Fort Worth, TX | Non-Bleb Forming, Trabecular Meshwork Canal Implant | 8.9 – 30.7 | 1.0 – 2.8 | Prospective and Retrospective | I, Moderate Quality, Strong Recommendation | Moderate° |
Trabectome | MicroSurgical Technology, Redmond, WA | Non-Bleb Forming, Trabecular Meshwork Canal Cleaving Approaches | 18–42 | 0 – 1.2 | Prospective and Retrospective | No Recommendation | Very Low† |
Kahook Dual Blade | New World Medical, Rancho Cucamonga, CA | Non-Bleb Forming, Trabecular Meshwork Canal Cleaving Approaches | 6.2 – 48.8 | 0.5 – 2.2 | Prospective and Retrospective | No Recommendation | Not Evaluated |
Gonioscopy-assisted transluminal trabeculotomy | NA | Non-Bleb Forming, Trabecular Meshwork Canal Cleaving Approaches | 36.2 – 68.2 | 1.1 – 3.5 | Retrospective | No Recommendation | Not Evaluated |
OMNI | Sight Sciences, Menlo Park, CA | Non-Bleb Forming, Trabecular Meshwork Canal Dilating & Cleaving Approaches | 19.2 – 44.7 | 0.0 – 2.5 | Prospective and Retrospective | No Recommendation | Not Evaluated |
ABiC with iTrack | Nova Eye Medical, Kent Town, Australia | Non-Bleb Forming, Trabecular Meshwork Canal Dilating Approaches | 32.5 – 39.2 | 0.9 −2.6 | Prospective and Retrospective | No Recommendation | Not Evaluated |
ECP | Endo Optiks, Little Silver, NJ | Non-Bleb Forming, Inflow Reducing Approaches | 34 – 57 | 0.0 – 1.5 | Retrospective | I-, Insufficient Quality, Discretionary Recommendation | Evaluated, no recommendation |
Xen Gel Stent | AbbVie Inc., North Chicago, Illinois | Bleb-Forming, Ab Interno Implants | 22.9 – 57.9 | 0.9 – 3.5 | Prospective and Retrospective | I-, Insufficient Quality, Discretionary Recommendation | Evaluated, no recommendation |
Either standalone or with concurrent phacoemulsification.
Depending on the number of implanted stents.
Only RCTs analyzed.
One RCT only.
AAO: American Academy of Ophthalmology; ABiC: Ab Interno Canaloplasty; ECP: Endoscopic cyclophotocoagulation; IOP: Intraocular Pressure